Gardasil’s FDA Approval Now Includes Some Vaginal And Vulvar Cancers
The US Food and Drug Administration (FDA) has approved Merck’s cervical vaccine Gardasil for protecting against vaginal and vulvar cancers caused by Human Papillomavirus (HPV) types 16 and 18 in girls and women aged from 9 to 26. The agency announced its decision to the press on Friday 12th September, in a FDA News page on its website.
